Gabapentin 600 mg Tablets Recalled Due to Dosage Strength Mix-Up
Sciegen Pharmaceuticals is recalling 4,392 bottles of Gabapentin 600 mg tablets after a pharmacist discovered some 800 mg tablets mixed into bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III classification indicates low risk of adverse health consequences per regulatory assessment. The recall describes a product quality issue (higher-dose tablets mixed with lower-dose tablets) without associated illness or injury reports.
Plain-English summary
Sciegen Pharmaceuticals Inc. is recalling 4,392 bottles of Gabapentin 600 mg tablets (500 tablets per bottle, Lot # G177092, Expiration 11/24) because some bottles contain Gabapentin 800 mg tablets mixed in with the labeled 600 mg tablets. The issue was discovered when a pharmacist reported the presence of the mismatched dosage.
The affected product was distributed nationwide in the United States and Puerto Rico. The recall applies to bottles with NDC 50228-177-05 and the specific lot number noted above.
Patients should not take any tablets from affected bottles without first verifying the actual dosage with their pharmacist. Taking an 800 mg tablet when expecting a 600 mg dose could result in higher-than-intended medication levels. Patients who believe they may have received an affected bottle should contact their pharmacist or healthcare provider immediately.
The recalled product
- Product
- GABAPENTIN (GABAPENTIN)
- Brand
- GABAPENTIN
- Manufacturer
- Sciegen Pharmaceuticals Inc
- Hazard
- dosage-mismatch
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # G177092
- Exp. 11/24
UPCs (11)
- 0350228180108
- 0350228180054
- 0350228181013
- 0350228178013
- 0350228181051
- 0350228179010
- 0350228180016
- 0350228177016
- 0350228179102
- 0350228178051
- 0350228177054
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · GABAPENTIN
- HighGabapentin 600 mg Tablets Recalled Due to Metformin Contamination
FDA (Drugs) · 2024-08-14
- ModerateGabapentin tablets recalled due to product mixup with foreign tablet
FDA (Drugs) · 2023-05-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27